Références
Áfra J., Sándor P.S. et Schoenen J., “Habituation of visual and intensity dependence of auditory evoked cortical potentials tend to normalize just before and during the migraine attack”, Cephalalgia, 2000;20:714-719.
Ambrosini A., de Noordhout A.M., Sandor P.S. et Schoenen J., “Electrophysiological studies in migraine: a comprehensive review of their interest and limitations”, Cephalalgia, 2003;23:13-31.
Ambrosini A. et Schoenen J., “Invasive pericranial nerve interventions”, Cephalalgia, 2016 Oct;36(12):1156-1169.
Ambrosini A., Vandenheede M., Rossi P., Aloj F., Sauli E., Pierelli F. et Schoenen J., “Suboccipital injection with a mixture of rapid- and long-acting steroids in cluster headache: a double-blind placebo-controlled study”, Pain, 2005;118:92-6.
Amundsen S., Nordeng H., Nezvalová-Henriksen K., Stovner L.J. et Spigset O., “Pharmacological treatment of migraine during pregnancy and breastfeeding”, Nat Rev Neurol, 2015 Apr;11(4):209-19.
Ashina M., “Migraine”, N Engl J Med, 2020 Nov 5;383(19):1866-1876.
Ashina M., Buse D.C., Ashina H., Pozo-Rosich P., Peres M.F.P., Lee M.J., Terwindt G.M., Halker Singh R., Tassorelli C., Do T.P., Mitsikostas D.D. et Dodick D.W., “Migraine: integrated approaches to clinical management and emerging treatments”, Lancet, 2021 Apr 17;397(10283):1505-1518.
Barrett C.F., van den Maagdenberg A.M.J.M., Frants R.R. et Ferrari M.D., “Familial hemiplegic migraine”, Adv Genet, 2008;63:57-83.
Bendik E.M., Tinkle B.T., Al-Shuik E., Levin L., Martin A., Thaler R., Atzinger C.L., Rueger J. et Martin V.T., “Joint hypermobility syndrome: A common clinical disorder associated with migraine in women”, Cephalalgia, 2011 Apr;31(5):603-13.
Bogdanov V.B., Multon S., Chauvel V., Bogdanova O.V., Prodanov D., Makarchuk M.Y. et Schoenen J., “Migraine preventive drugs differentially affect cortical spreading depression in rat”, Neurobiology of Disease, 2011;41:430-435.
Bogdanov V.B., Viganò A., Noirhomme Q., Bogdanova O.V., Guy N., Laureys S., Renshaw P.F., Dallel R., Phillips C. et Schoenen J., “Cerebral responses and role of the prefrontal cortex in conditioned pain modulation: an fMRI study in healthy subjects”, Behav Brain Res, 2015 Mar 15;281:187-98.
Breslau N, Davis GC. Migraine, physical health and psychiatric disorder: a prospective epidemiologic study in young adults, J Psychiatr Res., 1993 Apr-Jun;27(2):211-21.
Burch R., Rizzoli P. et Loder E., “The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys”, Headache, 2021 Jan;61(1):60-68.
Burstein R., Noseda R. et Fulton A.B., “Neurobiology of Photophobia”, J Neuroophthalmol, 2019 Mar;39(1):94-102.
Chalmer M.A., Esserlind A.L., Olesen J. et Hansen T.F., « Polygenic risk score: use in migraine research », J Headache Pain, 2018 Apr 5;19(1):29.
Charles A., et Hansen J.M., “Migraine aura: new ideas about cause, classification, and clinical significance”, Curr Opin Neurol, 2015 Jun;28(3):255-60.
Chauvel V., Multon S. et Schoenen J., “Estrogen-dependent effects of 5-hydroxytryptophan on cortical spreading depression in rat: modelling the serotonin-ovarian hormone interaction in migraine aura”, Cephalalgia, 2018 Mar;38(3):427-436.
Chauvel V., Schoenen J. et Multon S. (J.S. and S.M. contributed equally to this work), “Influence of Ovarian Hormones on Cortical Spreading Depression and Its Suppression by L-kynurenine in Rat”, PLoS ONE, 2013;8(12): e82279.
Choquet H., Yin J., Jacobson A.S., Horton B.H., Hoffmann T.J., Jorgenson E., Avins A.L. et Pressman A.R., “New and sex-specific migraine susceptibility loci identified from a multiethnic genome-wide meta-analysis”, Commun Biol, 2021 Jul 22;4(1):864.
Chou D.E., Shnayderman Yugrakh M., Winegarner D., Rowe V., Kuruvilla D. et Schoenen J., “Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial”, Cephalalgia, 2019 Jan;39(1):3-14.
Coppola G., Di Lenola D., Abagnale C., Ferrandes F., Sebastianelli G., Casillo F., Di Lorenzo C., Serrao M., Evangelista M., Schoenen J. et Pierelli F., “Short-latency afferent inhibition and somato-sensory evoked potentials during the migraine cycle: surrogate markers of a cycling cholinergic thalamo-cortical drive?”, J Headache Pain, 2020 Apr 16;21(1):34.
Delvaux V., Vandenheede M. et Schoenen J., « Céphalées explosives, “en coup de tonnerre” : faut-il s’inquiéter ? », Revue médicale de Liège, 2000, 55:910-914.
Demarquay G., Moisset X., Lantéri-Minet M., de Gaalon S., Donnet A., Giraud P., Guégan-Massardier E., Lucas C., Mawet J., Roos C., Valade D. et Ducros A., “Revised guidelines of the French Headache Society for the diagnosis and management of migraine in adults. Part 1: Diagnosis and assessment”, Rev. Neurol., Paris, 2021 Sep;177(7):725-733.
Denuelle M., Fabre N., Payoux P., Chollet F. et Geraud G., “Hypothalamic activation in spontaneous migraine attacks”, Headache, 2007 Nov-Dec;47(10):1418-26.
Di Lorenzo C., Pinto A., Ienca R., Coppola G., Sirianni G., Di Lorenzo G., Parisi V., Serrao M., Spagnoli A., Vestri A., Schoenen J., Donini L.M. et Pierelli F., “A Randomized Double-Blind, Cross-Over Trial of very Low-Calorie Diet in Overweight Migraine Patients: A Possible Role for Ketones?”, Nutrients, 2019 Jul 28;11(8):1742.
Di Stefano G., Yuan J.H., Cruccu G., Waxman S.G., Dib-Hajj S.D. et Truini A., “Familial trigeminal neuralgia – a systematic clinical study with a genomic screen of the neuronal electrogenisome”, Cephalalgia, 2020 Jul;40(8):767-777.
Diener H.C., Dodick D., Evers S., Holle D., Jensen R.H., Lipton R.B., Porreca F., Silberstein S. et Schwedt T., “Pathophysiology, prevention, and treatment of medication overuse headache”, Lancet Neurol, 2019 Sep;18(9):891-902.
Diener H.C., MacGregor E.A., Schoenen J., Steiner T.J., Muirhead N. et Sikes C., “Comparison of the efficacy and safety of eletriptan and zolmitriptan for the acute treatment of migraine: results of a multicenter, multi-dose, randomised clinical trial”, Neurology, 2002, 58, Suppl. 3, A290:P04.081.
Dodick D.W., “CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications”, Cephalalgia, 2019 Mar;39(3):445-458.
Drellia K., Kokoti L., Deligianni C.I., Papadopoulos D. et Mitsikostas D.D., « Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis », Cephalalgia, 2021 Jun;41(7):851-864.
Ducros A., de Gaalon S., Roos C., Donnet A., Giraud P., Guégan-Massardier E., Lantéri-Minet M., Lucas C., Mawet J., Moisset X., Valade D. et Demarquay G., “Revised guidelines of the French headache society for the diagnosis and management of migraine in adults. Part 2: Pharmacological treatment”, Rev Neurol, Paris, 2021 Sep;177(7):734-752.
Eadie M.J., “Hubert Airy, contemporary men of science and the migraine aura”, J R Coll Physicians Edinb., 2009;39:263-7.
Edmeads J., Láinez J.M., Brandes J.L., Schoenen J. et Freitag F., “Potential of the migraine disability assessment (MIDAS) questionnaire as a public health initiative and in clinical practice”, Neurology, 2001, 56 (Suppl 1):S29-S34.
Edvinsson L., Haanes K.A., Warfvinge K. et Krause D.N., « CGRP as the target of new migraine therapies – successful translation from bench to clinic », Nat Rev Neurol, 2018;14(6):338-350.
Eigenbrodt A.K., Ashina H., Khan S., Diener H.C., Mitsikostas D.D., Sinclair A.J., Pozo-Rosich P., Martelletti P., Ducros A., Lantéri-Minet M., Braschinsky M., Del Rio M.S., Daniel O., Özge A., Mammadbayli A., Arons M., Skorobogatykh K., Romanenko V., Terwindt G.M., Paemeleire K., Sacco S., Reuter U., Lampl C., Schytz H.W., Katsarava Z., Steiner T.J. et Ashina M., “Diagnosis and management of migraine in ten steps”, Nat Rev Neurol, 2021 Aug;17(8):501-514.
Färkkilä M., Diener H.C., Géraud G., Láinez M., Schoenen J., Harner N., Pilgrim A. et Reuter U. (for the COL MIG-202 study group), “Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study”, Lancet Neurology, 2012;11:405-413.
Fernández-de-las-Peñas C., Chaitow L. et Schoenen J., “Multidsiciplinary Management of Migraine: Pharmacological, Manual And Other Therapies”, Ed. Jones and Bartlett Learning (USA), Contemporary issues in physical therapy and rehabilitation medicine, 2012, 414 p.
Fernández-de-Las-Peñas C. et Cuadrado M.L., “Physical therapy for headaches”, Cephalalgia, 2016 Oct;36(12):1134-1142.
Fogang Y., Gérard P., De Pasqua V., Pepin J.L., Ndiaye M., Magis D. et Schoenen J., “Analysis and clinical correlates of 20 Hz photic driving on routine EEG in migraine”, Acta Neurol Belg, 2015 Mar;115(1):39-45.
Fontana A., « Essai contrôlé randomisé : quelle est la plus-value de l’assistance vidéo lors de séances d’éducation thérapeutique chez les patients migraineux », Mémoire de fin d’études de Master en sciences de la santé publique, ULg, année académique 2018-2019.
Fumal A., Laureys S., Di Clemente L., Boly M., Bohotin V., Vandenheede M., Coppola G., Salmon E., Kupers R. et Schoenen J., “Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine”, Brain, 2006;129:543-50.
Fumal A., Magis D. et Schoenen J., « Les céphalées par abus d’antalgiques », Revue médicale de Liège, 2006, 61(4):217-222.
Gaul C., Sándor P.S., Galli U., Palla S. et Ettlin D.A., “Orofacial migraine”, Cephalalgia, 2007 Aug;27(8) :950-2.
George K.M., Folsom A.R., Sharrett A.R., Mosley T.H., Gottesman R.F., Hamedani A.G. et Lutsey P.L., “Migraine Headache and Risk of Dementia in the Atherosclerosis Risk in Communities Neurocognitive Study”, Headache, 2020 May;60(5):946-953.
Gérardy P.-Y., Fumal A. et Schoenen J., « Épidémiologie et répercussions économiques des céphalées : une enquête parmi le personnel administratif, technique et ouvrier (PATO) de l’Université de Liège », Revue médicale de Liège, 2008, 63 :310-314.
Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019, GBD 2019 Diseases and Injuries Collaborators, Lancet, 2020 Oct 17;396(10258):1204-1222.
Gross E.C., Klement R.J., Schoenen J., D’Agostino D.P. et Fischer D., “Potential Protective Mechanisms of Ketone Bodies in Migraine Prevention”, Nutrients, 2019 Apr 10;11(4):811.
Gross E.C., Lisicki M., Fischer D., Sándor P.S. et Schoenen J., “The metabolic face of migraine – from pathophysiology to treatment”, Nat Rev Neurol, 2019 Nov;15(11):627-643.
Headache Classification Committee of the International Headache Society (IHS), The International Classification of Headache Disorders, 3rd ed., Cephalalgia, 2018 Jan;38(1):1-211.
Hepp Z., Dodick D.W., Varon S.F., Chia J., Matthew N., Gillard P., Hansen R.N. et Devine E.B., “Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis”, Cephalalgia, 2017 Apr;37(5):470-485.
Holroyd K.A., Cottrell C.K., O’Donnell F.J., Cordingley G.E., Drew J.B., Carlson B.W. et Himawan L., “Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial”, BMJ, 2010 Sep 29;341:c4871.
Horton B.T., MacLean A.R. et Craig W.M., “A new syndrome of vascular headache: results of treatment with histamine: preliminary report”, Mayo Clinic Proceedings, 1939;14:257.
Juprelle M. et Schoenen J., « Relaxation avec biofeedback musculaire dans les céphalées de type tension : analyse multifactorielle d’un groupe de 31 patients », Revue médicale de Liège, 1990;45:630-637.
Kelman L., “The triggers or precipitants of the acute migraine attack”, Cephalalgia, 2007 May;27(5):394-402.
Kosinski M., Bayliss M.S., Bjorner J.B. et al., “A six‐item short‐form survey for measuring headache impact: The HIT‐6”, Qual Life Res, 2003;12:963‐974.
Kostev K., Bohlken J. et Jacob L., “Association Between Migraine Headaches and Dementia in More than 7,400 Patients Followed in General Practices in the United Kingdom”, J Alzheimers Dis, 2019;71(1):353-360.
Kurth T. et Diener H.C., “Current views of the risk of stroke for migraine with and migraine without aura”, Curr Pain Headache Rep, 2006 Jun;10(3):214-20.
Kurth T., Rist P.M., Ridker P.M., Kotler G., Bubes V. et Buring J.E., “Association of Migraine With Aura and Other Risk Factors With Incident Cardiovascular Disease in Women”, JAMA, 2020 Jun 9;323(22):2281-2289.
Kurth T., Winter A.C., Eliassen A.H., Dushkes R., Mukamal K.J., Rimm E.B., Willett W.C., Manson J.E. et Rexrode K.M., “Migraine and risk of cardiovascular disease in women: prospective cohort study”, BMJ, 2016 May 31;353:i2610.
Laakso S.M., Hekali O., Kurdo G., Martola J., Sairanen T. et Atula S., “Trigeminal neuralgia in multiple sclerosis: Prevalence and association with demyelination”, Acta Neurol Scand, 2020 Aug;142(2):139-144.
Lanteri-Minet M., Valade D., Geraud G., Lucas C. et Donnet A., “Revised French guidelines for the diagnosis and management of migraine in adults and children”, J Headache Pain, 2014 Jan 8;15(1):2.
Lauritzen M., “Cortical spreading depression in migraine”, Cephalalgia, 2001 Sep;21(7):757-60.
Lempert T., Olesen J., Furman J., Waterston J., Seemungal B., Carey J., Bisdorff A., Versino M., Evers S. et Newman-Toker D., « Vestibular migraine: diagnostic criteria », J Vestib Res, 2012;22(4):167-72.
Linde K., Allais G., Brinkhaus B., Fei Y., Mehring M., Vertosick E.A., Vickers A. et White A.R., “Acupuncture for the prevention of episodic migraine”, Cochrane Database Syst Rev, 2016 Jun 28;2016(6):CD001218.
Lipton R.B., Bigal M.E., Ashina S., Burstein R., Silberstein S., Reed M.L., Serrano D. et Stewart W.F., “American Migraine Prevalence Prevention Advisory Group. Cutaneous allodynia in the migraine population”, Ann Neurol, 2008 Feb;63(2):148-58.
Lipton R.B., Cady R.K., Stewart W.F., Wilks K. et Hall C., “Diagnostic lessons from the spectrum study”, Neurology, 2002 May 14;58(9 Suppl 6):S27-31.
Lipton R.B., Scher A.I., Kolodner K., Liberman J., Steiner T.J. et Stewart W.F., “Migraine in the United States: epidemiology and patterns of health care use”, Neurology, 2002;58:885-894.
Lisicki M. et Schoenen J., “Metabolic treatments of migraine”, Expert Review of Neurotherapeutics, 2020;20(3):295-302.
Lisicki M. et Schoenen J., “Old habits die hard: Dietary patterns of migraine patients challenge our understanding of dietary triggers”, Front Neurol, 2021 (sous presse).
Lipton R.B., Stewart W.F., Sawyer J. et Edmeads J.G., “Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire”, Headache, 2001 Oct;41(9):854-61.
Lisicki M., D’Ostilio K., Coppola G., Scholtes F., Maertens de Noordhout A., Parisi V., Schoenen J. et Magis D., “Evidence of an increased neuronal activation-to-resting glucose uptake ratio in the visual cortex of migraine patients: a study comparing 18FDG-PET and visual evoked potentials”, J Headache Pain, 2018 Jul 5;19(1):49.
Loder E.W., “Menstrual migraine: pathophysiology, diagnosis, and impact”, Headache, 2006 Oct;46 Suppl 2:S55-60.
MacGregor E.A., “Menstrual migraine”, Curr Opin Neurol, 2008 Jun;21(3):309-15.
Maertens de Noordhout A. et Schoenen J., « Les algies faciales », Revue médicale de Liège, 1986, XLI(9) :342-348.
Maertens de Noordhout A., Timsit M., Timsit-Berthier M. et Schoenen J., “Contingent Negative Variation in Headache”, Annals of Neurology, 1986;19:78-80.
Magis D., Gerardy P.Y., Remacle J.M. et Schoenen J., “Sustained effectiveness of occipital nerve stimulation in drug-resistant chronic cluster headache”, Headache, 2011;51:1191-201.
Magis D. et Schoenen J., “Migraine: from genetics to environment”, Revue médicale de Liège, 2012, 67:349-358.
Manack A.N., Buse D.C. et Lipton R.B., “Chronic migraine: epidemiology and disease burden”, Curr Pain Headache Rep, 2011 Feb;15(1):70-8.
Mitsikostas D.D., Mantonakis L.I. et Chalarakis N.G., « Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches », Cephalalgia, 2011 Apr;31(5):550-61.
Moens G., Johannik K., Verbeek C. et Bulterys S., “The prevalence and characteristics of migraine among the Belgian working population”, Acta Neurol Belg, 2007 Sep;107(3):84-90.
Moskowitz M.A., “The neurobiology of vascular head pain”, Ann Neurol, 1984 Aug;16(2):157-68.
Nappi R.E., Sances G., Allais G., Terreno E., Benedetto C., Vaccaro V., Polatti F. et Facchinetti F., “Effects of an estrogen-free, desogestrel-containing oral contraceptive in women with migraine with aura: a prospective diary-based pilot study”, Contraception, 2011 Mar;83(3):223-8.
Obermann M., Yoon M.S., Dommes P., Kuznetsova J., Maschke M., Weimar C., Limmroth V., Diener H.C. et Katsarava Z., “Prevalence of trigeminal autonomic symptoms in migraine: a population-based study”, Cephalalgia, 2007 Jun;27(6):504-9.
Olesen J., Diener H.C., Schoenen J. et Hettiarachchi J., “No effect of eletriptan administration during the aura phase of migraine”, Europ J Neurol, 2004;11:671-677.
Osterhaus J.T., Townsend R.J., Gandek B. et Ware J.E. Jr., “Measuring the functional status and well-being of patients with migraine headache”, Headache, 1994 Jun;34(6):337-43.
Paemeleire K., Louis P., Magis D., Vandenheede M., Versijpt J., Vandersmissen B. et Schoenen J., “Diagnosis, pathophysiology and management of chronic migraine: a proposal of the Belgian Headache Society”, Acta Neurol Belg, 2015 Mar;115(1):1-17.
Paemeleire K., Magis D. et Schoenen J., “Medical treatment of migraine”, in Reference Module in Neuroscience and Biobehavioral Psychology, Elsevier, 2017, pp. 1-5.
Párdutz A. et Schoenen J., “NSAIDs in the acute treatment of migraine: a review of clinical and experimental data”, Pharmaceuticals, 2010;3:1966-1987.
Pohl H., Do T.P., García-Azorín D., Hansen J.M., Kristoffersen E.S., Nelson S.E., Obermann M., Sandor P.S., Schankin C.J., Schytz H.W., Sinclair A., Schoonman G.G. et Gantenbein A.R., “Green Flags and headache: A concept study using the Delphi method”, Headache, 2021 Feb;61(2):300-309.
Pohl H., Gantenbein A.R., Sandor P.S., Schoenen J. et Andrée C., “Interictal Burden of Cluster Headache: Results of the EUROLIGHT Cluster Headache Project, an Internet-Based, Cross-Sectional Study of People With Cluster Headache”, Headache, 2020 Feb;60(2):360-369.
Radat F, Swendsen J. Psychiatric comorbidity in migraine: a review, Cephalalgi,. 2005 Mar;25(3):165-78.
Relja M., Poole A.C., Schoenen J., Pascual J., Lei X. et Thompson C., “A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches”, Cephalalgia, 2007;27:492-503.
Reyngoudt H., Paemeleire K., Descamps B., De Deene Y. et Achten E., “31P-MRS demonstrates a reduction in high-energy phosphates in the occipital lobe of migraine without aura patients”, Cephalalgia, 2011 Sep;31(12):1243-53.
Sacco S., Merki-Feld G.S., Ægidius K.L., Bitzer J., Canonico M., Kurth T., Lampl C., Lidegaard Ø., MacGregor E.A., Maassen van den Brink A., Mitsikostas D.D., Nappi R.E., Ntaios G., Sandset P.M. et Martelletti P., “European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC)”, J Headache Pain, 2017 Oct 30;18(1):108.
Sajobi T.T., Amoozegar F., Wang M., Wiebe N., Fiest K.M., Patten S.B. et Jette N., “Global assessment of migraine severity measure: preliminary evidence of construct validity”, BMC Neurol, 2019 Apr 4;19(1):53.
Sándor P.S., Agosti R.M. et Schoenen J., “Migraine – advances in genetic research and possible link to neurophysiological abnormalities”, Schweizer Archiv für Neurologie und Psychiatrie, 2001;152:183-193.
Sándor P.S., Di Clemente M., Coppola G., Saenger U., Fumal A., Magis D., Seidel L., Agosti R.M. et Schoenen J., “Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial”, Neurology, 2005;64:713-15.
Scher A.I., Stewart W.F., Ricci J.A. et Lipton R.B., “Factors associated with the onset and remission of chronic daily headache in a population-based study”, Pain, 2003 Nov;106(1-2):81-9.
Schoenen J., « Les céphalées périmenstruelles. Contraception – Fertilité – Sexualité », 1985, 13(5):757-761.
Schoenen J., “Pathogenesis of migraine: the biobehavioural and hypoxia theories reconciled”, Acta Neurologica Belgica, 1994;94:79-86.
Schoenen J., « Épidémiologie et impact de la migraine », Cahiers de médecine du travail, 1995, XXXII:203-204.
Schoenen J., “Deficient habituation of evoked cortical potentials in migraine: a link between brain biology, behavior and trigeminovascular activation?”, Biomed & Pharmacother, 1996;50:71-78.
Schoenen J., “Cluster Headache”, Advanced Studies in Medicine, 2001;1:446-448.
Schoenen J., “Are migraine and headache associated with an increased risk of stroke in women?”, Nature Clinical Practice Neurology, 2006;2:74-75.
Schoenen J., “Botulinum toxin in headache treatment: finally a promising path?”, Cephalalgia, 2010;30:771-773.
Schoenen J. et Ambrosini A., “Update on noninvasive neuromodulation for migraine treatment-Vagus nerve stimulation”, Prog Brain Res, 2020;255:249-274.
Schoenen J., Baschi R., Magis D. et Coppola G., “Noninvasive neurostimulation methods for migraine therapy: The available evidence”, Cephalalgia, 2016 Oct;36(12):1170-1180.
Schoenen J., Bulcke J., Caekebeke J., Dehaene I., De Keyser J., Hildebrand G., Joffroy A., Laloux P., Louis P., Monseu G., Pierre P., Vanderlinden C., Sautois D. et Vanderberghe A., “Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study”, Cephalalgia, 1994;14:55-63.
Schoenen J., Burette P. et Materne P., « Foramen ovale perméable et migraines : association fortuite ou relation causale ? », Revue médicale de Liège, 2006, 61;9-15.
Schoenen J., Di Clemente L., Vandenheede M., Fumal A., De Pasqua V., Mouchamps M., Remacle J.M. et Maertens de Noordhout A., “Hypothalamic stimulation in chronic cluster headache: a pilot study of efficacy and mode of action”, Brain, 2005;128:940-947.
Schoenen J., Dodick D.W. et Sándor P.S., Comorbidity in Migraine, Oxford, Eds Wiley-Blackwell Publishing Ltd, 2011, 142 p.
Schoenen J., Franco G., Schretlen L. et Sobocki P., “Cost estimates of brain disorders in Belgium”, Acta Neurologica Belgica, 2006;106:208-214.
Schoenen J., Jacquy J. et Lenaerts M., “Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial”, Neurology, 1998;50:466-470.
Schoenen J., Jensen R.H., Lantéri-Minet M., Láinez M.J., Gaul C., Goodman A.M., Caparso A. et May A., “Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: A randomized, sham-controlled study”, Cephalalgia, 2013 Jul;33(10):816-30.
Schoenen J., Lecart M.P. et Morlion B., « Céphalées et facialgies », in Âge et douleur : un guide pratique, éds B. Morlion, M.P. Lecart, H. Verschueren et E. Vanduynhoven, Lannoo Campus, 2011, pp. 155-165.
Schoenen J., Lenarduzzi P. et Sianard-Gainko J., “Chronic headaches associated with analgesics and/or ergotamine abuse: a clinical survey of 434 consecutive out-patients”, in New Advances in Headache Research, F. Clifford Rose, ed. Smith-Gordon, 1989, pp. 255-259.
Schoenen J., Manise M., Nonis R., Gérard P. et Timmermans G., “Monoclonal antibodies blocking CGRP transmission: an update on their added value in migraine prevention”, Revue Neurologique, Paris, 2020;176:788-803.
Schoenen J. et Olesen J. (co-ed.), “Tension-type Headache: classification, mechanisms and treatment”, Frontiers in Headache Research, Vol. 3, New York, Raven Press, 1993, 291 p.
Schoenen J., Reuter U., Diener H.C., Pfeil J., Schwalen S., Schauble B. et van Oene J., “Factors predicting the probability of relapse after discontinuation of migraine preventive treatment with topiramate”, Cephalalgia, 2010; 30:1290-1295.
Schoenen J. et Sándor P., “Headache”, in Handbook of Pain Management, Eds R. Melzack et P.D. Wall, Chap. 33, London, Churchill Livingstone, 2003.
Schoenen J. et Sava S., “Tension-type Headache”, in Wall and Melzack’s Textbook of Pain, 6th Ed., eds S. MacMahon, M. Koltzenburg, I. Tracey et D. Turk, Chap.59, Elsevier, Amsterdam, 2013.
Schoenen J., Timmermans G., Nonis R., Manise M., Fumal A. et Gérard P., “Erenumab for migraine prevention in a 1-year compassionate use program: efficacy, tolerability and differences between clinical phenotypes” (soumis pour publication).
Schoenen J., Vandersmissen B., Jeangette S., Herroelen L., Vandenheede M., Gérard P. et Magis D., “Migraine prevention with a supraorbital transcutaneous stimulator: A randomized controlled trial”, Neurology, 2013;80:697-704.
Schoenen J., Wang W., Albert A. et Delwaide P.J., “Potentiation instead of habituation characterizes visual evoked potentials in migraine patients between attacks”, European Journal of Neurology, 1995;2:115-122.
Schulte L.H. et May A., “The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks”, Brain, 2016 Jul;139(Pt 7):1987-93.
Schürks M., Rist P.M., Bigal M.E., Buring J.E., Lipton R.B. et Kurth T., “Migraine and cardiovascular disease: systematic review and meta-analysis”, BMJ, 2009 Oct 27;339:b3914.
Schwedt T.J. et Schoenen J., “Patent foramen ovale and Migraine”, in Comorbidity in Migraine, Chapter 4, Eds Schoenen J., Dodick D.W. et Sándor P.S., Oxford, Wiley-Blackwell Publishing Ltd, 2011, 142 p., pp. 41-59.
Shapiro R.E., “What Will it Take to Move the Needle for Headache Disorders? An Advocacy Perspective”, Headache, 2020 Oct;60(9):2059-2077.
Silberstein S.D., Latsko M. et Schoenen J., “Preventive Antimigraine Drugs”, in Multidisciplinary Management of Migraine, Chap 10, Eds C. Fernandez-de-las-Peñas, L. Chaitow et J. Schoenen, Contemporary issues in Physical therapy and Rehabilitation Medicine, Jones and Bartlett Learning, Burlington (USA), 2012, pp. 91-102.
Somerville B.W., “The role of estradiol withdrawal in the etiology of menstrual migraine”, Neurology, 1972 Apr;22(4):355-65.
Streel S., Donneau A.F., Dardenne N., Hoge A., Albert A., Schoenen J. et Guillaume M., “Screening for the metabolic syndrome in subjects with migraine”, Cephalalgia, 2017 Oct;37(12):1180-1188.
Streel S., Donneau A.F., Hoge A., Albert A., Schoenen J. et Guillaume M., “One-year prevalence of migraine using a validated extended French version of the ID Migraine™: A Belgian population-based study”, Rev Neurol, Paris, 2015 Oct;171(10):707-14.
Swerts D.B., Benedetti F. et Peres M.F.P., “Different routes of administration in chronic migraine prevention lead to different placebo responses: a meta-analysis”, Pain, 2021 Jun 14, doi:10.1097/j.pain.0000000000002365.
Tfelt-Hansen P., Dahlof C., Pascual J., Lainez M., Henry P., Diener H.C., Schoenen J., Ferrari M.D., Saxena P.R. et Goadsby P.J., “Ergotamine: current place in the treatment of acute migraine attacks – European Consensus”, Brain, 2000;123:9-18.
Todd J., “The syndrome of Alice in Wonderland”, Can Med Assoc J., 1955;73(9).
Van den Bergh V., Amery W.K. et Waelkens J., “Trigger factors in migraine: a study conducted by the Belgian Migraine Society”, Headache, 1987 Apr;27(4):191-6.
Varkey E., Cider A., Carlsson J. et Linde M., “Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls”, Cephalalgia, 2011 Oct;31(14):1428-38.
Vigano A., Sasso d’Elia T., Sava S.L., Auvé M., De Pasqua V., Colosimo A., Di Piero V., Schoenen J. et Magis D., “Transcranial Direct Current Stimulation (tDCS) of the visual cortex: a proof-of-concept study based on interictal electrophysiological abnormalities in migraine”, Journal of Headache and Pain, 2013;14:23-31.
Waldie K.E., Hausmann M., Milne B.J. et Poulton R., “Migraine and cognitive function: a life-course study”, Neurology, 2002 Sep 24;59(6):904-8.
Ware J.E. Jr et Sherbourne C.D., “The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection”, Med Care, 1992 Jun;30(6):473-83.
Wells R.E., O’Connell N., Pierce C.R., Estave P., Penzien D.B., Loder E., Zeidan F. et Houle T.T., “Effectiveness of Mindfulness Meditation vs Headache Education for Adults With Migraine: A Randomized Clinical Trial”, JAMA Intern Med, 2021 Mar 1;181(3):317-328.
Whitmarsh T.E., Coleston-Shields D.M. et Steiner T.J., “Double-blind randomized placebo-controlled study of homoeopathic prophylaxis of migraine”, Cephalalgia, 1997 Aug;17(5):600-4.
Wijga A.H., Gehring U., van de Putte E.M., Koppelman G.H., Vader S., Schmits R.J.H., van der Wouden J.C. et Picavet H.S.J., “Headache in girls and boys growing up from age 11 to 20 years: the Prevention and Incidence of Asthma and Mite Allergy birth cohort study”, Pain, 2021 May 1;162(5):1449-1456.
Wijman C.A., Wolf P.A., Kase C.S., Kelly-Hayes M. et Beiser A.S., “Migrainous visual accompaniments are not rare in late life: the Framingham Study”, Stroke, 1998 Aug;29(8):1539-43.
Zanchin G., “Headache: an historical outline”, Chapter 25, Handb Clin Neurol, 2010;95:375-86.
